RUBY Rubius Therapeutics Inc.

8.46
-0.09  -1%
Previous Close 8.55
Open 8.41
Price To Book 2.2
Market Cap 675,115,259
Shares 79,800,858
Volume 218,282
Short Ratio
Av. Daily Volume 469,821
Stock charts supplied by TradingView

NewsSee all news

  1. Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

    RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply Future Clinical Trials

  2. Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  3. Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  4. Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer

    CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  5. Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

    CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Timing of data to be released once the first patient has been dosed - noted January 13, 2020.
RTX-134
Phenylketonuria (PKU)

Latest News

  1. Rubius Therapeutics Announces 2020 Objectives and Provides Operational Update at the 38th Annual J.P. Morgan Healthcare Conference

    RTX-240 Investigational New Drug Application for Cancer on File with U.S. Food and Drug Administration Rubius Manufacturing Facility Operational Nine Months Ahead of Schedule and Ready to Supply Future Clinical Trials

  2. Rubius Therapeutics Appoints Internationally Recognized Autoimmunity and Translational Immunology Leader Laurence Turka, M.D., as Chief Scientific Officer

    CAMBRIDGE, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  3. Rubius Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

    CAMBRIDGE, Mass., Jan. 02, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  4. Rubius Therapeutics Appoints Christina Coughlin, M.D., Ph.D., as Chief Medical Officer

    CAMBRIDGE, Mass., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  5. Rubius Therapeutics Appoints Anne Prener, M.D., Ph.D., to its Board of Directors

    CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  6. Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

    CAMBRIDGE, Mass., Dec. 16, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently

  7. Flagship Pioneering Unveils Cellarity, the First Company to Discover Medicines Targeting Cell Behavior

    CAMBRIDGE, Mass., Dec. 10, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, unveiled Cellarity, a first-of-its-kind therapeutics company that is discovering and developing medicines

  8. Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

    CAMBRIDGE, Mass., Dec. 2, 2019 /PRNewswire/ -- Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros

  9. Rubius Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress

    CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  10. Rubius Therapeutics to Participate in Jefferies London Healthcare Conference

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  11. Rubius Therapeutics Appoints Maiken Keson-Brookes as Chief Legal Officer and Corporate Secretary

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  12. Rubius Therapeutics Highlights Preclinical Oncology Data at Society for Immunotherapy of Cancer Annual Meeting and AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

    CAMBRIDGE, Mass., Nov. 08, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  13. Rubius Therapeutics to Announce Third Quarter 2019 Financial Results

    CAMBRIDGE, Mass., Nov. 05, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of

  14. Entrada Therapeutics Appoints Nathan Dowden as Chief Operating Officer

    BOSTON, Nov. 4, 2019 /PRNewswire/ -- Entrada Therapeutics, a biotechnology company dedicated to transforming the treatment of devastating diseases through the intracellular delivery of biologics, today announced the

  15. Flagship Pioneering Unveils Cygnal Therapeutics

    CAMBRIDGE, Mass., Oct. 8, 2019 /PRNewswire/ -- Flagship Pioneering, a unique life sciences innovation enterprise, today unveiled Cygnal Therapeutics. Founded in 2017 in Flagship Labs, Flagship's innovation foundry,

  16. Flagship Pioneering Unveils Omega Therapeutics and Appoints Seasoned BioPharma Executive Mahesh Karande as President and Chief Executive Officer

    Omega Therapeutics is unleashing the human genome's native capacity to regulate genes and cure disease for a new era of genomic medicine The Company's platform is focused on precise tuning of Insulated Genomic

  17. Rubius Therapeutics to Participate in 17th Annual Morgan Stanley Global Healthcare Conference

    CAMBRIDGE, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class